Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30094545 | 0.78 | SMN1; SMN2 (0.38) | MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL30094544 | 0.78 | SMN1; SMN2 (0.38) | MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL20482185 | 0.78 | — | — | |
| SCHEMBL23845538 | 0.78 | SMN1; SMN2 (0.38) | MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL3085479 | 0.78 | SMN1; SMN2 (0.38) | MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL23845535 | 0.78 | SMN1; SMN2 (0.38) | MAPTDGAT1SMN1; SMN2 | |
| SCHEMBL18122404 | 0.75 | PIK3CD (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL15202858 | 0.75 | PIK3CD (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL21936045 | 0.74 | PRMT5 (0.30) | — | |
| SCHEMBL23845425 | 0.74 | PIK3CD (0.41) | MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-4121426-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | Akebia Therapeutics Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115515948-A | PHD inhibitor compounds, compositions and uses | 阿克比治疗有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2022-03-01 | — | — | US | disclosed |
| WO-2021188938-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-110770226-A | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018153508-A2 | SULFOXIMINE GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | MAPT 42/4885DGAT1 2036/4885ALDH1A1 862/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | MAPT 42/4885DGAT1 2036/4885ALDH1A1 862/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | MAPT 38/4885DGAT1 1894/4885ALDH1A1 955/4885 |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | MAPT 42/4885DGAT1 2036/4885ALDH1A1 862/4885 |
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | MAPT 4498/4885DGAT1 1936/4885ALDH1A1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.